Slides
Page 1
43rd Annual J.P. Morgan Healthcare Conference Serge Saxonov CEO and Co-founder January 13, 2025
Page 2
© 10X GENOMICS, INC. 2025 22 Certain statements in this presentation and the accompanying oral commentary are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “see,” “estimate,” “predict,” “potential,” “would,” “likely,” “seek” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.’s expected financial results, operations, the features, performance, capabilities, uses, costs, demand, opportunities, growth, drivers and adoption of current and potential future solutions as well as product roadmap, expected development directions and expected release of potential products. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.’s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s most recently-filed 10-K and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements. In light of the foregoing, investors are urged not to place undue reliance on any forward-looking statement or third-party data in reaching any conclusion or making any investment decision about any securities of the Company. 10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. The information contained on, or that may be accessed through, the Company’s website is not incorporated by reference into, and is not a part of, this presentation. 10x Genomics’ products are for research use only (RUO) and are not for use in diagnostic procedures. Forward-Looking Statements
Page 3
© 10X GENOMICS, INC. 2025 Our Mission Accelerate the mastery of biology to advance human health 3
Page 4
© 10X GENOMICS, INC. 2025 Interactions of millions of different molecules and molecular machines Enormous complexity within each cell Cells form tissues, which form organs Each tissue comprises a large diversity of cells and cell types Each cell contains its own set of expressed genes 40 trillion cells in the human body And needs to be measured at large scale and high resolution 4 Biology Is Immensely Complex
Page 5
© 10X GENOMICS, INC. 2025 Biology Can Only Be Understood at the Cellular Level 5 Understand how the parts fit together Spatial Analysis Single Cell Analysis Compile the parts list of human biology Measure mixtures which misses underlying biology Bulk Analysis
Page 6
© 10X GENOMICS, INC. 2025 10x Is Powering the Single Cell and Spatial Revolutions Chromium Single Cell Spatial 6 Instruments, consumables and software to measure biology at large scale and unprecedented resolution Xenium Visium
Page 7
© 10X GENOMICS, INC. 2025 ~2,600 Linked Reads First launch 2015 2016 2017 2018 2019 2020 2021 2022 Single Cell Gene Expression Immune Profiling Epigenetics Proteomics Next GEM Visium Spatial New platforms Chromium X Series 10x Cloud Visium FFPE Xenium Platform Visium CytAssist Single Cell Gene Expression Flex 2023 Xenium Panels Flex + Proteins Visium + Proteins 77 GEM-X Visium HD Xenium 5K Automation Capabilities 2024 Proven Innovation Engine — Single cell — Spatial Chromium Connect Multiome Major Products Patents and Applications 30+
Page 8
© 10X GENOMICS, INC. 2025 88 Deep in-field expertise 180+ technical and applications specialists Dedicated and specialized sales team 200+ commissionable salesforce Strong customer partnerships ~10,000 customer papers in high-impact journals Robust customer service and support 98% Customer Satisfaction Score Comprehensive bioinformatics tools and resources Broad Commercial Reach Scaled for Growth
Page 9
© 10X GENOMICS, INC. 2025 High Quality ● ISO9001; pursuing ISO13485 ● Cross-functional product development process with R&D Supply Chain Management ● Global supplier network and management ● Rigorous controls and risk mitigation 99 Scaled Operations to Deliver High Quality Globally 9 Reliable Delivery Business Continuity Exceptional Service Scaled Global Operations to Support the Full Range of Customer Segments Pleasanton Leiden Singapore Taiwan Global Distribution Consistency ● Uniform production within and between lots ● Vertical integration to drive efficient cost structure
Page 10
© 10X GENOMICS, INC. 2025 Note: 2024 revenue, instruments sold and cash represent preliminary and unaudited results. Cash includes cash, cash equivalents and marketable securities. Cumulative instruments sold as of December 31, 2024. 10 Preliminary 2024 Results 10 ~$611M Total 2024 Revenue ~$493M Consumables Revenue 1,050+ Instruments Sold (7,000+ Cumulative Instruments Sold) ~$393M Cash Year of Transition ✓ Launched multiple major products redefining all three platforms with Xenium Prime 5K, Visium HD and Chromium GEM-X architecture ✓ Reduced single cell pricing with new products to unlock elasticity and promote large-scale projects ✓ Reorganized sales structure to align for growth and scale for the future, transitioning more than 40% of U.S. accounts in Q3 2024
Page 11
© 10X GENOMICS, INC. 2025 11 Scale of measurements: plexy, number of analytes Resolution: spatial & cellular insights ELISAs Low High IHC IF & ISH Flow cytometry High-content imaging & cell-based assays 11 Low High PCR/qPCR Western blots Bulk next-gen sequencing Replacing the Legacy Toolkit Across Life Sciences
Page 12
Fueling Discoveries Across Life Sciences ~10,000 customer papers in high-impact journals +40% growth year over year
Page 13
© 10X GENOMICS, INC. 2025 Note: External analysis plus analyst estimates 10x Today ~$611M A $13B Serviceable Addressable Market Today Future Growth Drivers Expansion in mainstream biology ~80% of current customers self-identify as “early adopters or innovators” 1 2 Expansion in translational research 3 Outsized growth in biopharma Opportunity to grow biopharma revenue from ~20% to ~50% of overall business Product innovation Reduction in costs, expansion in new applications and simplification of workflows4$13B $6B single cell $7B spatial $75B global life science research tools market FFPE and fixation compatibility particularly important for translational research All life science labs assumed to adopt single cell or spatial solutions at current experimental spend levels Life science labs using single cell, spatial or adjacent techniques assumed to adopt single cell or spatial solutions at current experimental spend levels Note: Market opportunity based on third-party analysis and management estimates. $21B $10B single cell $11B spatial SAM TAM 13 Large Opportunity in Life Science Research
Page 14
© 10X GENOMICS, INC. 2025Note: 2024 Chromium revenue represents preliminary and unaudited results. Cumulative Chromium instruments sold and publications are as of December 31, 2024. Gold Standard in Single Cell 5,800+ Cumulative Chromium Instruments Sold ~$408M 2024 Chromium Product Revenue 8,800+ Chromium Publications in High-Impact Journals 1414 Category-Defining Chromium Platform ● Catalyzed Single Cell revolution ● Broad menu of assays, analytes and applications ● Best performance, data quality and ease of use ● Accessible cost at any scale ● Extensive ecosystem of customers, datasets, protocols and papers ● Uniquely capable of analyzing FFPE samples
Page 15
© 10X GENOMICS, INC. 2025 1515 Setting a New Standard for Scale and Performance. At Lower Cost. GEM-X Universal 3’ On-Chip Multiplexing for 3’ and 5’ Chromium XoGEM-X Universal 5’ GEM-X Flex Automated Library Construction Fixation for Universal 3’ and 5’ Whole Blood Fixation Intracellular Protein Automated Cell Annotation 2.5 Million Cells in a Single Run 1¢ Per Cell $600 Per Sample At Any Scale New Products Major New Capabilities Democratizing AccessEnabling Large Scale Lowering Costs 2024 Single Cell Product Launches
Page 16
© 10X GENOMICS, INC. 2025 1616Note: 2024 Spatial revenue represents preliminary and unaudited results. Cumulative Spatial instruments sold and publications are as of December 31, 2024. ● Bringing together the worlds of histology and genomics ● Versatile: whole transcriptome, targeted, fully custom, protein and RNA ● 8 independent Xenium benchmarking studies: superior performance in sensitivity, specificity, cell typing, and more ● Easy-to-run workflows with intuitive software for best-in-class experience ● Seamless pathology integration: same section H&E and IF Leading the Spatial Revolution Rapidly Growing Visium and Xenium Platforms 1,200+ Cumulative Spatial Instruments Sold ~$179M 2024 Spatial Product Revenue 33% YoY Growth 850+ Spatial Publications in High-Impact Journals
Page 17
© 10X GENOMICS, INC. 2025 “2024 marks a watershed moment in spatial transcriptomics with the arrival of Xenium 5K and Visium HD – technologies that have transformed our ability to map and understand the intricate language of cells in their precise spatial domains, revealing biological complexity at unprecedented resolution.” Zexian Zeng PhD, Peking University Xenium Multimodal Cell Segmentation Optimized membrane, interior and nuclear stains Advanced, purpose-built, machine learning algorithm Visium HD Whole transcriptome analysis at single cell-scale Critically enabled by the Visium CytAssist instrument Compatible with FFPE, fresh frozen and fixed frozen samples Xenium Prime 5K 5,000 genes for a broad range of applications in human and mouse Customizable add-on content Xenium Human Immuno-Oncology Panel 380 genes spanning tissue, immune and cancer biology Customizable add-on content Spatial Software Updates Space Ranger analysis in 10x Cloud, high-resolution image export, multilayer stain visualization and more 17 “Seeing Xenium 5K data reminded me of the excitement I experienced when I saw single cell RNA-seq data for the first time. Now, we can identify relevant molecular pathways in human diseases and explore new biological hypotheses, all from one glass slide!” Kevin Wei, MD, PhD, Harvard Medical School 17 2024 Spatial Product Launches Delivering Higher Resolution, Much Larger Plex and More Applications “The integration of cutting-edge 10x technologies, such as Visium HD and Flex snRNA-seq, provides an unparalleled opportunity to uncover the molecular determinants driving macrophage plasticity in breast cancer patients – a phenomenon once regarded as an impenetrable ‘black box.’ By leveraging their exceptional cloud-based solutions, 10x eliminates traditional bottlenecks in data analysis, accelerating breakthroughs in clinical oncology and transforming the pace of scientific discovery.” Nir Ben Chetrit, PhD, Weill Cornell Medical College
Page 18
© 10X GENOMICS, INC. 2025 Product Ecosystem Chromium Visium Xenium 18 10x Platforms Produce Complementary Data
Page 19
Measure More Biology ● More analytes, applications and multiomics ● Higher resolution, sensitivity and multiplexing ● More scale, throughput, cells and tissues Improve End-to-End Workflows ● Workflow robustness, experimental logistics ● Sample prep, sample breadth ● Data analysis, data processing, efficient insights Lower Cost ● Lower cost per cell, tissue area, sample, experiment and project 19 © 10X GENOMICS, INC. 2025 Future Product Development Directions
Page 20
© 10X GENOMICS, INC. 2025 20 New, Specialized Sales Organization to Drive Growth at Scale Accelerate Xenium adoption 20 Expand the ecosystem Drive growth through new applications, larger scale and routine use Deliver outsized growth in biopharma Capital Equipment Expertise New Customer Acquisition Customer Utilization and Expansion Pharma and Biotech Expertise
Page 21
© 10X GENOMICS, INC. 2025 21 Translational Cohort Studies …and many more 21 Profiling samples from over 1,000 long-term survivors in hard-to-treat cancers with Visium HD A cellular, location-based approach for disease biomarker analysis to empower and accelerate drug discovery efforts using AI to infer cell-to-cell interactions from the spatial data of thousands of samples Consortium of universities, hospitals and industry to study 6,000 cancer patients and determine why certain patients respond to immunotherapy while others do not Mapping 50 million human cells from 10,000 people to identify unique genomic fingerprints of autoimmune diseases, heart diseases and cancer with GEM-X Spatial multiomics dataset from ~7,000 patients for the identification of new disease biology, patient subtypes, biomarkers and drug types Evaluating thousands of tumor and immune samples to find biomarkers of progression from early precursor conditions to multiple myeloma and identify patients likely to benefit from earlier treatment
Page 22
© 10X GENOMICS, INC. 2025 Single Cell & Spatial Use Cases 22 Discovery Stages (2–5 Years) Preclinical (1–3 Years) Clinical (3–7 Years) Post Market (Many Years) Target Identification Target Validation Hit Discovery & Assay Development Hit-to-Lead & Lead Optimization Preclinical Development Clinical Trials Phase 1 & 2 Clinical Trials Phase 3 Post-Market Surveillance Utility Across the Drug Development Continuum Identify cells, genes & proteins implicated in disease Study cell composition of disease to identify target cells Identify and validate targets with CRISPR screens Select promising compounds with single cell readouts after drug exposures Understand mechanism of action Assess safety and toxicity Assess biodistribution of therapy across tissues Assess and adjust dosage levels in future trials based on data collected Identify biomarkers for response / resistance Emerging application: research studies to assess recurrence / MRD
Page 23
© 10X GENOMICS, INC. 2025 Functional Genomics at Scale Large-Scale CRISPR Screens 2323 ● Big emerging wave in academia and biopharma ● Powerful approach to understand gene function, map regulatory networks and determine causality ● Enables massively parallel experimentation, discovery of drug targets and testing of potential interventions ● 2.5M cells in a single run ● Exceptional sensitivity and efficient cell recovery ● Easy workflow and high robustness ● Low cost and efficient sequencing for routine use “We now envision a Perturbation Cell Atlas as a generative causal foundation model to unify human cell biology.” Chromium Flex: Designed for Scale Exponential Growth in Publications Cell Press, Vol. 187, Issue 17: “Toward a foundation model of causal cell and tissue biology with a Perturbation Cell and Tissue Atlas” Organoid + CRISPR screen Single cell capture Single cell phenotype Deep learning intercellular genetics Toward a foundation model of causal cell and tissue biology with a Perturbation Cell and Tissue Atlas Combinatorial single-cell CRISPR screens by direct guide RNA capture and targeted sequencing A platform for multimodal in vivo pooled genetic screens reveals regulators of liver function Building, Benchmarking, and Exploring Perturbative Maps of Transcriptional and Morphological Data Spatially Resolved in vivo CRISPR Screen Sequencing via Perturb-DBiT Massively Parallel CRISPR-Based Genetic Perturbation Screening at Single-Cell Resolution
Page 24
© 10X GENOMICS, INC. 2025 24 Accelerate Understanding of biology • Creation of new medicines • Development of new diagnostics 10x Experiments AI Models Large-Scale Data Molecules, Cells, Tissues Mastering Biology with 10x and AI
Page 25
© 10X GENOMICS, INC. 2025 25 1 2 3 4 Multiple pillars of robust growth ahead with expansion opportunities in mainstream biology research, translational applications and biopharma 10x is the leader at the nexus of foundational technologies and large markets Innovation engine and leadership drive sustained competitive differentiation Scaled organization poised to drive to a best-in-class financial profile Key Takeaways
Page 26
Thank You